FAGR Fagron SA

Fagron increases share capital through exercise subscription rights

Fagron increases share capital through exercise subscription rights

Regulated information

Nazareth (Belgium)/Rotterdam (The Netherlands), 6 June 2025 – 7PM CET

Fagron increases share capital through exercise subscription rights

Fagron announces that as a result of the exercise of subscription rights, 85,000 new shares have been issued on 6 June 2025.

In accordance with the Belgian transparency legislation, Fagron notes that its total share capital currently amounts to € 504,303,905.59. The total number of shares with voting rights after the issue amounts to 73,313,904 which is also the total number of voting rights (the ‘denominator’). The total number of rights (formerly known as warrants) to subscribe to not yet issued shares with voting rights amounts to 1,465,833.

Further information

Ignacio Artola

Global Investor Relations Leader

Tel.

About Fagron

Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in 35 countries around the world.

Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Attachment



EN
06/06/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fagron SA

Robert Jan Vos ... (+2)
  • Robert Jan Vos
  • Usama Tariq

Fagron N.V. : A serial compounder in the pharma land, we raise our tar...

We’ve raised our medium term estimates for Fagron, expecting mid-term sales growth of 8.3% versus guidance (high single digit), likely topped by 2% via M&A and further supported by rising (AA-OB at 20.8% for 2027) margins (21% by 2027). At ~13.3x (AA-OB) 2026 P/E, Fagron is valued attractively, leading us to raise our target price to €27 per share.

Stijn Demeester
  • Stijn Demeester

Fagron/1H25 preview: Organic growth sound, FX bites/BUY

We update our model and target price to reflect recent adverse FX trends, with our organic growth assumptions unchanged. We reiterate our BUY on Fagron, an ING Benelux Favourite, as its strengthening track record, high visibility on organic growth and attractive valuation at c.9x/8x 2026F/2027F EV/EBITDA, lay the grounds for a re-rating as the company further executes on its growth agenda.

Guy Sips ... (+9)
  • Guy Sips
  • Hilde Van Boxstael
  • Kristof Samoy
  • Livio Luyten
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi

Dynamic Top Pick List Update July: Removing Fagron and Melexis, Adding...

Since the last publication of our Dynamic Top Pick List on 5 June 2025, our selection has seen again a nice outperformance versus the reverence indices (AEX, Bel20 and Eurostoxx50) of on average 3.3%. Our July update brings 3 adjustments to the list : Since being added to the list in December 2024, Fagron's share price has surged +/-22%, driven by strong Q1 2025 results and robust growth across all regions. Fagron reaffirmed its FY25 guidance and unveiled its “Compounding for Growth” strategy, ...

Stijn Demeester
  • Stijn Demeester

Fagron/Confident ambitions not yet priced in/BUY

We raise our target price to €26 per share from €22.5 and reiterate our BUY recommendation, as we find Fagron's recent step-up in growth targets is not yet priced in. Given high visibility on organic growth, attractive value and a strengthening track record, Fagron remains on the ING Benelux Favourites list.

Wim Lewi
  • Wim Lewi

Dollar Weakness The impact on our Benelux Coverage

In general, a weaker USD has a negative impact on Benelux stocks, particularly for companies with significant exports to the US. In this note we selected a list of companies with high US export exposure and we examine the potential impact on FY25 earninings. On top of the weak dollar, rising trade tensions or the introduction of tariffs further harm Benelux exporters. As the dollar depreciates against the euro, European goods become costlier for American consumers. At the same time, revenues ear...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch